Keystone Financial Services Takes Position in Cencora, Inc. $COR

Keystone Financial Services bought a new position in shares of Cencora, Inc. (NYSE:COR) during the second quarter, HoldingsChannel.com reports. The institutional investor bought 1,081 shares of the company’s stock, valued at approximately $324,000.

A number of other large investors have also recently added to or reduced their stakes in the company. Atlantic Edge Private Wealth Management LLC increased its stake in shares of Cencora by 70.0% during the 2nd quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock worth $25,000 after purchasing an additional 35 shares during the last quarter. Cornerstone Planning Group LLC grew its holdings in Cencora by 106.7% during the first quarter. Cornerstone Planning Group LLC now owns 93 shares of the company’s stock worth $26,000 after purchasing an additional 48 shares during the period. Costello Asset Management INC acquired a new position in Cencora during the first quarter worth approximately $28,000. University of Texas Texas AM Investment Management Co. bought a new stake in Cencora in the first quarter valued at approximately $39,000. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in shares of Cencora in the second quarter valued at approximately $61,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Wall Street Analyst Weigh In

COR has been the topic of a number of research analyst reports. Evercore ISI set a $400.00 price target on Cencora and gave the company an “outperform” rating in a research note on Thursday. Morgan Stanley set a $330.00 price objective on shares of Cencora and gave the company an “equal weight” rating in a research report on Wednesday, July 16th. Wells Fargo & Company raised their target price on shares of Cencora from $337.00 to $354.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 13th. Mizuho upped their price target on shares of Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a research note on Thursday. Finally, Weiss Ratings reissued a “buy (b-)” rating on shares of Cencora in a report on Thursday, October 30th. Eight investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, Cencora presently has a consensus rating of “Moderate Buy” and a consensus target price of $351.50.

Insider Transactions at Cencora

In other Cencora news, Chairman Steven H. Collis sold 31,350 shares of the firm’s stock in a transaction dated Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total value of $9,087,111.00. Following the transaction, the chairman directly owned 305,913 shares of the company’s stock, valued at $88,671,942.18. This trade represents a 9.30% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Robert P. Mauch sold 5,097 shares of the company’s stock in a transaction that occurred on Monday, October 20th. The stock was sold at an average price of $326.80, for a total transaction of $1,665,699.60. Following the sale, the chief executive officer directly owned 37,940 shares of the company’s stock, valued at approximately $12,398,792. This trade represents a 11.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 41,544 shares of company stock worth $12,230,941 over the last quarter. Corporate insiders own 10.80% of the company’s stock.

Cencora Price Performance

Shares of Cencora stock opened at $360.56 on Friday. The company has a quick ratio of 0.53, a current ratio of 0.90 and a debt-to-equity ratio of 3.64. The stock has a market capitalization of $69.90 billion, a price-to-earnings ratio of 37.09, a price-to-earnings-growth ratio of 1.56 and a beta of 0.63. Cencora, Inc. has a twelve month low of $223.92 and a twelve month high of $364.36. The company has a 50-day simple moving average of $314.27 and a two-hundred day simple moving average of $299.34.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, beating the consensus estimate of $3.79 by $0.05. The firm had revenue of $83.73 billion during the quarter, compared to analysts’ expectations of $83.36 billion. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The company’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.34 EPS. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Analysts forecast that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 14th will be given a dividend of $0.60 per share. This is a positive change from Cencora’s previous quarterly dividend of $0.55. This represents a $2.40 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend is Friday, November 14th. Cencora’s dividend payout ratio (DPR) is currently 30.19%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.